Invasive Breast Cancer, Breast Cancer Mortality Increased Long Term After DCIS
THURSDAY, Jan. 25, 2024 -- Women with non-screen-detected ductal carcinoma in situ have an increased risk for invasive breast cancer and breast cancer death, according to a study published online Jan. 24 in The BMJ.
Gurdeep S. Mannu, M.B.B.S.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 25, 2024 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Investor Update - January 16, 2024 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Media News - January 16, 2024 Category: Pharmaceuticals Source Type: news
Clinical Breast Exam Rarely Detects Second Breast Cancer After DCIS
FRIDAY, Jan. 12, 2024 -- For patients undergoing surveillance following diagnosis and treatment of ductal carcinoma in situ (DCIS), very few second breast cancers are detected by clinical breast examination by a physician, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 12, 2024 Category: Pharmaceuticals Source Type: news
Clinical Exams Fall Short in Second Breast Cancer Detection Clinical Exams Fall Short in Second Breast Cancer Detection
A decade-long surveillance study shows clinical breast examinations are largely ineffective in detecting second cancers in women treated for ductal carcinoma in situ.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
No Added Benefit From Chemo in This Breast Cancer Subtype No Added Benefit From Chemo in This Breast Cancer Subtype
Adding chemotherapy to endocrine therapy for women with ER-positive, HER2-negative invasive lobular carcinoma does not improve survival outcomes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 28, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Benign breast disease found on percutaneous biopsy ups cancer risk
Benign breast disease diagnosed through percutaneous biopsy increases the overall risk of developing breast cancer, according to research published December 13 in JAMA Surgery. A team led by Dr. Mark Sherman from the Mayo Clinic in Jacksonville, FL, found that presence of the disease on percutaneous biopsy is tied to a similar degree of increased breast cancer risk compared with surgically diagnosed benign breast disease. It also reported that the risks of both invasive breast cancer and ductal carcinoma in situ (DCIS) remained elevated among patients with the disease compared with the general population. “The finding...
Source: AuntMinnie.com Headlines - December 13, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Womens Imaging Source Type: news
Women With Very Early Breast Cancer May Safely Skip Radiation Rx: Study
FRIDAY, Dec. 8, 2023 -- Some women with a very early form of breast cancer known as ductal carcinoma in situ (DCIS) can safely skip follow-up radiation therapy after surgery, new research suggests.Results from a sophisticated genetic test are key... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 8, 2023 Category: General Medicine Source Type: news
CEM shows value as surveillance imaging tool
Contrast-enhanced mammography (CEM) has utility as a surveillance tool for women with a personal history of breast cancer, according to research presented December 6 at the San Antonio Breast Cancer Symposium. In her talk, Julia Matheson from the University of Melbourne in Australia shared research indicating that CEM surveillance leads to increased detection of clinically significant breast lesions, as well as lower interval cancer rates. “CEM increases the sensitivity of surveillance programs for women with a personal history of breast cancer,” Matheson said. Annual mammography with or without supplemental ultra...
Source: AuntMinnie.com Headlines - December 6, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Breast Source Type: news
DBT plus mammo detects breast cancers with higher histologic grades
Digital breast tomosynthesis (DBT) plus synthesized mammography screening leads to higher detection of early-stage invasive breast cancers grades 2 or 3, according to research published December 5 in Radiology.
A team led by Stefanie Weigel, MD, from the University of Münster in Germany, found in its subanalysis of the Tomosynthesis plus Synthesized Mammography (TOSYMA) study that this combined method detects more cancers than mammography alone. The group also found that women ages 60-70 with dense breasts had the highest breast cancer rate in the study.
“These results suggest that DBT plus synthesized mammography scr...
Source: AuntMinnie.com Headlines - December 6, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Breast Breast Imaging Source Type: news
CEM confirms effectiveness of cryoablation
CHICAGO -- Contrast-enhanced mammography (CEM) confirms the effectiveness of ultrasound-guided cryoablation and could serve as a reliable annual follow-up exam, findings presented November 26 at the RSNA annual meeting suggest. In her presentation, Federica di Naro, MD, from Azienda Ospedaliero-Universitaria Careggi in Florence, Italy discussed her team’s results, which showed that combining CEM and re-evaluation with biopsy in selected breast cancer histology proves the efficacy of ultrasound-guided cryoabaltion and CEM’s reliability.“CEM is a valuable tool to define the effectiveness of cryoablation,” di Naro sai...
Source: AuntMinnie.com Headlines - December 1, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Womens Imaging Breast Imaging RSNA 2023 Source Type: news
Biomarker model predicts breast cancer risk without racial bias
CHICAGO -- A new breast cancer risk assessment technique that uses mammography biomarkers shows no racial bias, according to research presented November 29 at the RSNA meeting.The findings offer another way to foster breast cancer early detection, improve patient survival rates across different populations, and reduce disparity in survival rates, said study lead author Leslie Lamb, MD, of Massachusetts General Hospital (MGH) in Boston in a statement. “In the domain of precision medicine, risk-based screening has been elusive because we have not been able to accurately evaluate a woman’s risk of developing breast cance...
Source: AuntMinnie.com Headlines - November 29, 2023 Category: Radiology Authors: Liz Carey Tags: Subspecialties Womens Imaging Breast Imaging RSNA 2023 Source Type: news
F-18 fluciclovine PET/CT detects metastatic breast cancer
In this study, Mushtaq and colleagues enrolled 20 women with new or suspected recurrent ILC from a previous trial at Emory University. Patients had undergone PET/CT scans after IV administration of F-18 fluciclovine and Ga-68 PSMA on separate days. For comparison, conventional imaging included CT or bone scans in 13 patients and F-18 FDG-PET in seven patients.An image from Mushtaq's presentation showing a comparison between PET radiotracers in a patient with ILC. Image courtesy of Aliza Mushtaq, MD, Emory University.Three experts assessed radiotracer uptake per patient as well as in three regions per patient: ipsilateral a...
Source: AuntMinnie.com Headlines - November 27, 2023 Category: Radiology Authors: Will Morton Tags: Molecular Imaging Breast Imaging 2023 Source Type: news
ASTRO proposes new guidelines for aggressive breast cancer and DCIS
The American Society for Radiation Oncology (ASTRO) has released a proposed update to clinical practice guidelines for partial breast radiation as an alternative to whole breast radiation for early-stage invasive breast cancer and ductal carcinoma in situ (DCIS).
ASTRO’s recommendations are based on evidence from major clinical trials, said Janice Lyons, MD, chair of the guideline task force at the University Hospitals Seidman Cancer Center in Cleveland, OH, in a statement released by the society. The new guidance also addresses aspects related to the technical delivery of partial breast irradiation (PBI), including do...
Source: AuntMinnie.com Headlines - November 17, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Subspecialties Radiation Oncology Source Type: news
ASTRO Updates Guidelines on Partial Breast Irradiation for Early Invasive Cancer
(MedPage Today) -- The American Society for Radiation Oncology (ASTRO) updated their guidelines on partial breast irradiation (PBI) for patients with early-stage invasive breast cancer or ductal carcinoma in situ (DCIS).
These new guidelines take... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 16, 2023 Category: Hematology Source Type: news
